The UFMylation pathway is impaired in Alzheimer’s disease
There are marked changes in the UFMylation pathway in human AD brain. These changes are significantly associated with pathological tau, supporting the idea that the UFMylation cascade might indeed act as a modifier of tau pathology in human brain. Our study further nominates UFSP2 as an attractive target to reduce the hyperUFMylation observed in AD brain but also underscores the critical need to identify risks and benefits of manipulating the UFMylation pathway as potential therapeutic avenue for AD.
Authors
- Emily C. Craver (ORCID: https://orcid.org/0000-0003-0334-9606)
- Dennis W. Dickson (ORCID: https://orcid.org/0000-0001-7189-7917)
- Guojun Bu (ORCID: https://orcid.org/0000-0003-3491-1016)
- Michael G. Heckman (ORCID: https://orcid.org/0000-0003-3770-9331)
- Bailey Rawlinson
- Melissa E. Murray (ORCID: https://orcid.org/0000-0001-7379-2545)
- Fabienne C. Fiesel (ORCID: https://orcid.org/0000-0002-1919-9676)
- Tingxiang Yan (ORCID: https://orcid.org/0000-0002-2068-859X)
- Chia‐Chen Liu (ORCID: https://orcid.org/0000-0001-7203-3926)
- Nilüfer Ertekin‐Taner (ORCID: https://orcid.org/0000-0003-4436-8889)
- Wolfdieter Springer (ORCID: https://orcid.org/0000-0002-1178-3149)
- Zhenkun Lou (ORCID: https://orcid.org/0000-0003-1938-3091)
- Xue Wang (ORCID: https://orcid.org/0000-0002-6298-1858)
Institutions
- Hong Kong University of Science and Technology (HK)
- Jacksonville College (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University of Hong Kong (HK)
Publication Details
- Journal
- Molecular Neurodegeneration
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13024-024-00784-y
- Citations
- 11
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.57
Funders
- Florida Department of Health
- Bundesamt für Gesundheit
- National Institutes of Health